LCZ 696

Known as: LCZ-696, LCZ696 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2018
020406020052018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Heart failure (HF) is one of the leading causes of morbidity, mortality, and health care expenditures in the US and worldwide… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
AIMS The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2015
2015
BACKGROUND Increases in serum creatinine with renin-angiotensin-aldosterone system (RAAS) inhibitors can lead to unnecessary… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
BACKGROUND Angiotensin receptor neprilysin inhibitors (ARNi), beyond blocking angiotensin II signaling, augment natriuretic… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with… (More)
  • figure 1
  • table 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2014
2014
AIM To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison… (More)
  • table 2
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Heart failure with preserved ejection fraction is associated with substantial morbidity and mortality, but effective… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension… (More)
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND LCZ696 is a first-in-class inhibitor of the angiotensin II receptor and neprilysin. We aimed to establish whether the… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?